Menu
← Oncology Approval Tracker
FDA DECISION ·
Enzalutamide tablets
enzalutamide · Sandoz
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First generic of Xtandi tablets for castration-resistant prostate cancer, metastatic castration-sensitive disease or nonmetastatic castration-sensitive disease with high-risk biochemical recurrence.
LAMPGEN ANALYSIS
Why it matters
FDA’s first-generic listing applies to the tablet presentation. Each prostate cancer setting carries distinct staging and treatment-history criteria.
What research teams should watch
Check tablet sourcing and formulary status and document the disease setting. FDA approval alone does not establish a product's launch date.
PRIMARY RECORDS